Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA

NCT: NCT07854262 · RECRUITING

NCT IDNCT07854262
StatusRECRUITING
Start Date2024-11-20
Completion2026-10-14
SponsorAnkara City Hospital Bilkent (OTHER)
First posted
Last updated

Brief Summary

The aim of this study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) combined with complete decongestive therapy (CDT) compared with CDT alone in patients with breast cancer-related lymphedema. Female patients with unilateral Stage II upper-extremity lymphedema related to breast cancer will be included. Participants will receive either complete decongestive therapy alone or complete decongestive therapy combined with extracorporeal shock wave therapy. Clinical outcomes will be evaluated before treatment, immediately after treatment, and at 1 and 3 months after treatment. Primary outcomes will include limb circumference difference, volumetric measurements, and ultrasonographic assessment of skin and subcutaneous tissue thickness. Secondary outcomes will include upper-extremity function, quality of life, and pain.

Frequently Asked Questions

What is EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA?

EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA is a clinical trial registered under NCT07854262. Current status: RECRUITING.

What is the status of NCT07854262?

The current status of NCT07854262 (EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA) is: RECRUITING.

When did EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA start?

EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA started on 2024-11-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑